Streetbeat News

Products Services

ALGS

Aligos Therapeutics' stock price has increased following the announcement of positive clinical data from its Phase 1 studies in HBV and NASH, which was presented at Hep-DART 2023.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 9:32 pm

COIN

SQ

Block Inc (NYSE:SQ), founded by Jack Dorsey, has launched Bitkey, a self-custody Bitcoin wallet available in over 95 countries. Bitkey, which can be used as a mobile app or hardware storage, features a two-of-three multi-signature wallet and secure hardware device with recovery tools. Block's Q3 2023 revenue was $5.62 billion, with Cash App contributing $1.16 billion. The company's Bitcoin investments yielded a $44 million profit. Coinbase Global Inc (NASDAQ:COIN) and Cash App are the first global partners for Bitkey.

Portfolio Pulse from Khyathi Dalal

December 07, 2023 | 9:23 pm

RKLB

Rocket Lab has signed a launch services agreement with the Korea Advanced Institute of Science and Technology (KAIST) to launch an Earth observation satellite on a rideshare mission scheduled for the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 9:21 pm

ADVM

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) will present initial Phase 2 efficacy and safety data from the LUNA study at the 47th Annual Meeting of the Macula Society. The data concerns Ixoberogene soroparvovec (Ixo-vec), a gene therapy for Neovascular Age-Related Macular Degeneration. The presentation is scheduled for February 8th, 2024. Adverum will also host a conference call to discuss the data, with details to be announced later. The presentation will be available on Adverum's website.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 9:18 pm

TPB

Zig-Zag, the renowned rolling paper brand, has launched its 'Vintage' apparel collection as a tribute to its long-standing history in the smoking industry. The collection includes a variety of streetwear items featuring classic Zig-Zag iconography. The brand is licensed in the U.S. and Canada by North Atlantic Operating Company, L.P., a subsidiary of Turning Point Brands, Inc. (NYSE:TPB). The launch comes ahead of Zig-Zag's 145th anniversary in 2024 and aligns with consumer demand, potentially aiding in the brand's expansion into new segments. Turning Point Brands' stock saw a slight increase of 0.88% to $24.11 per share on Thursday afternoon.

Portfolio Pulse from Joana Scopel

December 07, 2023 | 9:17 pm

SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) shares surged over 75% after the company announced it received Fast Track Designation from the FDA for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. This follows the IND clearance received in mid-November. The stock closed up 68.4% at $5.76, with trading volume significantly higher than the average.

Portfolio Pulse from Ryan Gustafson

December 07, 2023 | 9:05 pm

NXST

NewsNation and The CW Network attracted over 4 million viewers for the GOP Presidential primary debate, with NewsNation achieving a record 1.6 million viewers and The CW hitting its highest primetime audience since 2018. The debate was particularly successful in the New York City market. NewsNation's growth is highlighted by a 73% increase in total viewers and a 90% rise among adults 25 to 54 in weekday primetime year-to-date. The event's success is a testament to the network's growth since its inception three years ago.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 8:39 pm

AMD

GOOGL

QQQ

US major indexes have risen due to lower-than-anticipated jobless claims. The Nasdaq, in particular, benefited from gains in AMD and Google, which have both made significant AI announcements recently.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 8:31 pm

PCVX

PFE

Mizuho Securities initiated coverage on Vaxcyte Inc (PCVX), a vaccine company, with a Buy rating and a price target of $69. Vaxcyte's lead asset VAX-24, targeting pneumococcal disease, is set to enter Phase 3 in 2024. Vaxcyte's technology could disrupt Pfizer's (PFE) long-standing near monopoly in pneumococcal vaccines. Vaxcyte's vaccines, VAX-24 and VAX-31, cover more serotypes than Pfizer's current vaccines, potentially offering broader disease prevention.

Portfolio Pulse from Vandana Singh

December 07, 2023 | 8:27 pm

CPB

Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Campbell Soup Company (CPB) but increased the price target from $44 to $47. The upgrade is based on CPB's evolution in direct store delivery (DSD) for its Snacks division, which includes consolidating mixing centers and depots, updating technology for inventory monitoring and ordering, and improving automation. The Goldfish brand's strong position among teens and new product innovations are expected to help expand its market share. The anticipated FTC approval and closure of the SOVO acquisition by the end of FY24 also contribute to the positive outlook. CPB's shares rose by 1.23% to $43.77.

Portfolio Pulse from Shivani Kumaresan

December 07, 2023 | 8:20 pm